New shot aims to match existing treatment for rare autoimmune disease
NCT ID NCT05263934
Summary
This study is testing whether a new long-acting injectable drug called depemokimab works as well as an existing drug called mepolizumab for adults with relapsing or hard-to-treat EGPA, a rare autoimmune disease. Both drugs are given as injections alongside standard steroid medications. The main goal is to see if participants can achieve and maintain remission—meaning very low disease activity with minimal steroid use—over one year of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Denver, Colorado, 80206, United States
-
GSK Investigational Site
Gainesville, Florida, 32610, United States
-
GSK Investigational Site
Rochester, Minnesota, 55905, United States
-
GSK Investigational Site
New York, New York, 10021, United States
-
GSK Investigational Site
Charlotte, North Carolina, 28211, United States
-
GSK Investigational Site
Tulsa, Oklahoma, 74136, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19104, United States
-
GSK Investigational Site
Pittsburgh, Pennsylvania, 15261, United States
-
GSK Investigational Site
Norfolk, Virginia, 23507, United States
-
GSK Investigational Site
La Plata, B1900, Argentina
-
GSK Investigational Site
San Miguel de Tucumán, T4000, Argentina
-
GSK Investigational Site
Graz, 8036, Austria
-
GSK Investigational Site
Brussels, 1070, Belgium
-
GSK Investigational Site
Leuven, 3000, Belgium
-
GSK Investigational Site
São Paulo, 4023900, Brazil
-
GSK Investigational Site
Toronto, Ontario, M5T 3A9, Canada
-
GSK Investigational Site
Toronto, Ontario, M5T 3L9, Canada
-
GSK Investigational Site
Beijing, 100005, China
-
GSK Investigational Site
Guangzhou, 510163, China
-
GSK Investigational Site
Hefei, 230001, China
-
GSK Investigational Site
Nanjing, 210006, China
-
GSK Investigational Site
Qingdao, 266071, China
-
GSK Investigational Site
Shanghai, 200032, China
-
GSK Investigational Site
Shenzhen, 518020, China
-
GSK Investigational Site
Wenzhou, 325000, China
-
GSK Investigational Site
Brest, 29609, France
-
GSK Investigational Site
La Roche-sur-Yon, 85925, France
-
GSK Investigational Site
Lille, 59037, France
-
GSK Investigational Site
Montpellier, 34295, France
-
GSK Investigational Site
Nantes, 44093, France
-
GSK Investigational Site
Paris, 75014, France
-
GSK Investigational Site
Suresnes, 92150, France
-
GSK Investigational Site
Toulouse, 31059, France
-
GSK Investigational Site
Freiburg im Breisgau, 79106, Germany
-
GSK Investigational Site
Minden, 32429, Germany
-
GSK Investigational Site
Budapest, 1023, Hungary
-
GSK Investigational Site
Ramat Gan, 52621, Israel
-
GSK Investigational Site
Bari, 70124, Italy
-
GSK Investigational Site
Brescia, 25123, Italy
-
GSK Investigational Site
Florence, 50134, Italy
-
GSK Investigational Site
Milan, 20132, Italy
-
GSK Investigational Site
Milan, 20162, Italy
-
GSK Investigational Site
Pavia, 27100, Italy
-
GSK Investigational Site
Pisa, 56126, Italy
-
GSK Investigational Site
Roma, 00128, Italy
-
GSK Investigational Site
Torrette AN, 60126, Italy
-
GSK Investigational Site
Treviso, 31100, Italy
-
GSK Investigational Site
Kanagawa, 247-8533, Japan
-
GSK Investigational Site
Kanagawa, 252-0392, Japan
-
GSK Investigational Site
Saitama, 350-8550, Japan
-
GSK Investigational Site
Tokyo, 162-8666, Japan
-
GSK Investigational Site
Tokyo, 181-8611, Japan
-
GSK Investigational Site
Groningen, 9713 GZ, Netherlands
-
GSK Investigational Site
Leiden, 2333 ZA, Netherlands
-
GSK Investigational Site
Gdansk, 80-952, Poland
-
GSK Investigational Site
Lodz, 90-153, Poland
-
GSK Investigational Site
Warsaw, 01-138, Poland
-
GSK Investigational Site
Lisbon, 1649-035, Portugal
-
GSK Investigational Site
Porto, 4099-001, Portugal
-
GSK Investigational Site
Gwangju, 61469, South Korea
-
GSK Investigational Site
Seoul, 05505, South Korea
-
GSK Investigational Site
Seoul, 06351, South Korea
-
GSK Investigational Site
Seoul, 06591, South Korea
-
GSK Investigational Site
Seoul, 3080, South Korea
-
GSK Investigational Site
Badalona, 08930, Spain
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Barcelona, 08036, Spain
-
GSK Investigational Site
Granada, 18014, Spain
-
GSK Investigational Site
Granada, 18016, Spain
-
GSK Investigational Site
Pamplona, 31008, Spain
-
GSK Investigational Site
Valencia, 46026, Spain
-
GSK Investigational Site
Zaragoza, 50009, Spain
-
GSK Investigational Site
Malmo, SE-205 02, Sweden
-
GSK Investigational Site
Birmingham, B15 2GW, United Kingdom
-
GSK Investigational Site
Cambridge, CB2 2QQ, United Kingdom
-
GSK Investigational Site
London, SE1 7EH, United Kingdom
Conditions
Explore the condition pages connected to this study.